

Develop Anti-Cancer Therapeutics for HER2 low Gastric Cancers by Combining Targeting Peptide and NanoCarrier

KMD Bio Ltd



ONCOLOGY	Candidate
Product Type	Drug Delivery System : Antibody Conjugated NanoParticles (ACNP)
Indication	Stomach Cancer, Breast Cancer, Hepatobiliary Cancer
Target	HER2 overexpressed solid cancers, HER2 low (mild/moderate expressed) solid cancers
MoA(Mechanism of Action)	Combining Active CancerTargeting (Receptor Mediated Endocytosis) and Passive Cancer Targeting (Enhanced Permeability and Retention)
Competitiveness	<ol style="list-style-type: none"> 1. Highly effective cancer targeting 2. Deliver exponential number of payload to targeted cancer. 3. Utilize non-favorable payloads either being insoluble or highly toxic to normal cell 4. Expand pipelines by switching targeting peptides and/or payloads 5. Driving synergy by double targeting and dual payloads (loading two different targeting agents and/or payloads)
Development Stage	Candidate
Route of Administration	IV